AxoGen, Inc. provided preliminary unaudited earnings guidance for the fourth quarter and full year ended December 31, 2017. Fourth quarter revenue is expected to be at least $16.5 million, up 45% compared to the fourth quarter of 2016 revenue of $11.4 million. Full year 2017 revenue is expected to be at least $60.0 million, up 46% compared to 2016 revenue of $41.1 million. Management increases its full year 2017 revenue guidance to at least $60.0 million. Management reiterates its full year 2017 gross margin guidance to exceed 80%. Management reiterates 2018 annual revenue will grow at least 40% over 2017 revenue and gross margins will remain above 80%.